(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 July 2014 (10.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/106602 A1

(51) International Patent Classification:
A61P 37/00 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/EP2013/077898

(22) International Filing Date:
23 December 2013 (23.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/748,201 2 January 2013 (02.01.2013) US

(71) Applicant: **GLENMARK PHARMACEUTICALS S.A.** [CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(72) Inventors: **ATTINGER, Antoine**; c/o Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **BACK, Jonathan Albert**; c/o Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **BLEIN, Stanislas**; c/o Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **LISSILAA, Rami**; c/o Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH). **SKEGRO, Darko**; c/o Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(74) Agent: **SCHOELLHORN, Andreas**; Latscha Schöllhorn Partner AG, Aeschenvorstadt 55, CH-4051 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/106602 A1

(54) Title: ANTIBODIES THAT BIND TO TL1A AND THEIR USES

(57) Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1Acomprising a heavy chain CDR1comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, 5 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.